A Single Center Pilot Study to Evaluate Real Time Passive and Active High-Frequency Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology
Conditions: Major Depressive Disorder
Sponsor: Takeda

This may include, but is not limited to, redaction of the following: 


•
Title: A Single Center Pilot Study to Evaluate Real Time Passive and Active High-Frequency 
Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable 
Technology 
NCT Number:  NCT03067506
Protocol Approve Date: 10 March 2017
Certain information within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable 
information or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential 
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.

1.0 TITLE PAGE
TAKEDA PHARMACEUTICALS
TAKEDA PHARMACEUTICALS PROTOCOL
A Single Center Pilot Study to Evaluate Real Time Passive and Active High-Frequency Cognitive 
and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology 
Short Title: Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital 
Wearable Technology 
Sponsor:
Takeda Pharmaceuticals U.S.A., Inc.
One Takeda Parkway
Deerfield, IL 60015
Study Number:
MDD-5003
IND Number:
Not Applicable
EudraCT Number:
Not applicable
Compound:
Not applicable
Date:
10 March 2017
Version/Amendment 
Number:
01
Amendment History: 
Date
Amendment Number
Amendment Type
Region
08 December 2016
Initial version
Not applicable
United Kingdom
10 March 2017
01
Substantial
United Kingdom
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom may be participating in 
the study. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, and 
applicable institutional review committee and regulatory agencies to enable conduct of the study.

Study No. MDD-5003
Page 2 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
1.0
ADMINISTRATIVE INFORMATION 
1.1
Contacts
A separate contact information list will be provided to each site.
Takeda Development Center (TDC) sponsored investigators per individual country requirements 
will be provided with emergency medical contact information cards to be carried by each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study site. Information on service providers is given in Section 3.1 and relevant guidelines 
provided to the site.
Contact Type/Role
Contact
Serious prestudy event and serious 
adverse event reporting
Takeda Development Center (Americas)
Pharmacovigilance Department
Fax number: 224-554-1052
Adverse event, special situation reports 
and product quality issues
Email:
Phone 
Medical Monitor
(medical advice on protocol) and 
Responsible Medical Officer 
(carries overall responsibility for the 
conduct of the study)
Takeda US Medical Affairs
PPD
PPD

Study No. MDD-5003
Page 3 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
1.2
Approval 
REPRESENTATIVES OF TAKEDA
This study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this study protocol and also in accordance with the following:
!
The ethical principles that have their origin in the Declaration of Helsinki.
!
International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!
All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible Takeda Medical Officer (and other signatories, as applicable) can 
be found on the signature page.
Electronic Signatures are provided on the last page of this document.
Date
Date
Date
Date
Date
PPD
PPD
PPD
PPD
PPD

Study No. MDD-5003
Page 4 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
INVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Investigator’s Brochure, package 
insert and any other product information provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and also to protect the rights, safety, privacy, 
and well-being of study subjects in accordance with the following:

The ethical principles that have their origin in the Declaration of Helsinki.

International Conference on Harmonisation, E6 Good Clinical Practice: Consolidated 
Guideline.

All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.

Regulatory requirements for reporting adverse events defined in Section 10.2 of this protocol.

Terms outlined in the study site agreement.

Responsibilities of the Investigator (Appendix B).
I further authorize that my personal information may be processed and transferred in accordance 
with the uses contemplated in Appendix D of this protocol.
Signature of Investigator
Date
Investigator Name (print or type)
Investigator’s Title
Location of Facility (City, State/Provence)
Location of Facility (Country)

Study No. MDD-5003
Page 5 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
1.3
Protocol Amendment No. 01 Summary of Changes
This document describes changes in references to Protocol Incorporating Amendment No. 01 
dated 28 February 2017.
The primary purpose of this amendment is to update the protocol to expand the selection criteria.
Minor grammatical and editorial changes are included for clarification purpose only. Full details 
on changes of text are given in Appendix E. The following is a summary of the changes made in 
the amendment:
1. Removed the requirement that subjects must have switched to a new antidepressant 
(monotherapy) for 24 weeks or less.
Rationale: This modification was deemed necessary to enhance enrollment into the study.
2.
Removed the requirement that subjects must have been treated for more than a year without 
any period of remission.
Rationale: This modification was deemed necessary to enhance enrollment into the study.
3. Clarified the documentation requirements for the Screening Visit. 
Rationale: To provide further clarification regarding the documentation required at the time of 
screening.
4.
Rationale: Clarification and update to the section to ensure accurate representation of protocol 
procedures and corrected the timing of the mood questions.
5. Removed reference to drug in Section 12.2.
Rationale: This is an unblinded noninterventional study.
6.
Rationale: Clarified the name of the scale.
CCI
CCI

Study No. MDD-5003
Page 6 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
TABLE OF CONTENTS
1.0
ADMINISTRATIVE INFORMATION ...........................................................................2
1.1
Contacts.....................................................................................................................2
1.2
Approval....................................................................................................................3
1.3
Protocol Amendment No. 01 Summary of Changes ...................................................5
2.0
STUDY SUMMARY ....................................................................................................10
3.0
STUDY REFERENCE INFORMATION ......................................................................12
3.1
Study-Related Responsibilities.................................................................................12
3.2
Coordinating Investigator.........................................................................................12
3.3
List of Abbreviations ...............................................................................................13
3.4
Corporate Identification...........................................................................................13
4.0
INTRODUCTION.........................................................................................................14
4.1
Background .............................................................................................................14
4.1.1
Cognitive Impairment in MDD ..........................................................................14
4.1.2
Functional Implications of Cognitive Dysfunction in MDD................................14
4.1.3
Assessment of Cognition and Mood on Mobile and Wearable Technology in 
Patients With Depression ...................................................................................15
4.2
Rationale for the Proposed Study.............................................................................16
4.3
Benefit/Risk Profile .................................................................................................16
5.0
STUDY OBJECTIVES AND ENDPOINTS..................................................................17
5.1
Objectives................................................................................................................17
5.1.1
Coprimary Objectives ........................................................................................17
5.1.2
Additional Objectives.........................................................................................17
5.2
Endpoints.................................................................................................................17
5.2.1
Coprimary Endpoints .........................................................................................17
5.2.2
Additional Endpoints .........................................................................................17
6.0
STUDY DESIGN AND DESCRIPTION.......................................................................18
6.1
Study Design ...........................................................................................................18
6.2
Justification for Study Design, Dose, and Endpoints ................................................20
6.3
Premature Termination or Suspension of Study or Study Site...................................20
6.3.1
Criteria for Premature Termination or Suspension of the Study..........................20
6.3.2
Criteria for Premature Termination or Suspension of Study Sites .......................20
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)..............................................................................21
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS..............22

Study No. MDD-5003
Page 7 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
7.1
Inclusion Criteria .....................................................................................................22
7.2
Exclusion Criteria ....................................................................................................22
7.3
Criteria for Discontinuation or Withdrawal of a Subject...........................................23
7.4
Procedures for Discontinuation or Withdrawal of a Subject......................................24
8.0
CLINICAL STUDY MATERIAL MANAGEMENT.....................................................25
8.1
Study Materials........................................................................................................25
8.1.1
Ancillary Materials ............................................................................................25
8.1.2
Storage...............................................................................................................25
8.1.3
Accountability and Return of Ancillary Materials ..............................................25
9.0
STUDY PLAN ..............................................................................................................26
9.1
Study Procedures.....................................................................................................26
9.1.1
Informed Consent Procedure..............................................................................26
9.1.2
Demographics, Medical History, and Medication History Procedure..................26
9.1.3
Documentation of Concomitant Medications......................................................26
9.1.4
Documentation of Concurrent Medical Conditions.............................................26
9.1.5
Procedures for Clinical Laboratory Samples.......................................................26
9.1.6
Contraception and Pregnancy Avoidance Procedure...........................................27
9.1.7
Pregnancy ..........................................................................................................27
9.1.8
Electrocardiogram Procedure .............................................................................27
9.1.9
Documentation of Screen Failure .......................................................................27
9.1.10 Documentation of Study Entrance......................................................................27
9.1.11 Wearable Technology Data................................................................................27
9.1.11.1
Wearable Cognitive Assessment..............................................................28
9.1.11.2
Wearable Mood Assessment....................................................................28
9.1.11.3
Wearable Passive Sensor Data.................................................................28
9.1.12 Subject Self-Report Measures ............................................................................28
9.1.12.1
...................................................................................................28
9.1.12.2
.............28
9.1.12.3
..........................................................................29
9.1.13 CANTAB Cognitive Assessments......................................................................29
9.1.13.1
Emotion Recognition Test .......................................................................29
9.1.13.2
Spatial Working Memory ........................................................................29
9.1.13.3
The Rapid Visual Information Processing................................................30
9.1.14 Semistructured Interviews..................................................................................30
CCI
CCI
CCI

Study No. MDD-5003
Page 8 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
9.1.14.1
Study Entry Interview..............................................................................30
9.1.14.2
End of Study Interview............................................................................30
9.2
Schedule of Observations and Procedures................................................................30
9.2.1
Screening...........................................................................................................30
9.2.2
Study Entrance (Visit 1).....................................................................................31
9.2.3
Visits 2, 3, and 4 ................................................................................................31
9.2.4
Phone Contacts: Reminder and Support Calls.....................................................31
9.2.5
Final Visit or Early Termination.........................................................................32
9.2.6
Poststudy Care ...................................................................................................32
9.3
Biological Sample Retention and Destruction ..........................................................32
10.0
PRESTUDY EVENTS AND ADVERSE EVENTS.......................................................33
10.1
Definitions...............................................................................................................33
10.1.1 Prestudy Event...................................................................................................33
10.1.2 AEs....................................................................................................................33
10.1.3 Special Situation Reports and Product Quality Issues.........................................33
10.1.4 Serious Adverse Events......................................................................................34
10.1.5 Severity of Prestudy Events and AEs .................................................................34
10.1.6 Relationship to Study Procedures.......................................................................34
10.1.7 Start Date...........................................................................................................34
10.1.8 Stop Date...........................................................................................................35
10.1.9 Frequency ..........................................................................................................35
10.1.10
Outcome.......................................................................................................35
10.2
Procedures...............................................................................................................35
10.2.1 Collection and Reporting of Spontaneous AEs, SSRs, and Product Quality 
Issues Related to a Takeda Product ....................................................................35
10.2.2 Serious Prestudy Event and SAE Collection Period............................................36
10.2.3 Collection and Reporting of SAEs......................................................................36
10.3
Follow-up of SAEs ..................................................................................................37
10.3.1 Safety Reporting to Investigators, IRBs, and Regulatory Authorities..................37
11.0
STUDY-SPECIFIC COMMITTEES .............................................................................38
12.0
DATA HANDLING AND RECORDKEEPING............................................................39
12.1
CRFs (Paper)...........................................................................................................39
12.2
Record Retention .....................................................................................................39
13.0
STATISTICAL METHODS..........................................................................................41
13.1
Statistical and Analytical Plans ................................................................................41

Study No. MDD-5003
Page 9 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
13.1.1 Analysis Sets......................................................................................................41
13.1.2 Analysis of Demographics and Other Baseline Characteristics ...........................41
13.1.3 Analysis of Wearable Technology Data Collection Compliance (Coprimary 
Aim) ..................................................................................................................41
13.1.4 Analysis of Validity of Wearable and Mood Testing (Coprimary Aim) ..............41
13.1.5 Qualitative Analysis...........................................................................................42
13.1.6 Safety Analysis ..................................................................................................43
13.2
Interim Analysis and Criteria for Early Termination ................................................43
13.3
Determination of Sample Size..................................................................................43
14.0
QUALITY CONTROL AND QUALITY ASSURANCE...............................................44
14.1
Study-Site Monitoring Visits ...................................................................................44
14.2
Protocol Deviations..................................................................................................44
14.3
Quality Assurance Audits and Regulatory Agency Inspections ................................44
15.0
ETHICAL ASPECTS OF THE STUDY........................................................................45
15.1
IRB and/or IEC Approval ........................................................................................45
15.2
Subject Information, Informed Consent, and Subject Authorization .........................45
15.3
Subject Confidentiality ............................................................................................46
15.4
Publication, Disclosure, and Clinical Trial Registration Policy.................................47
15.4.1 Publication and Disclosure.................................................................................47
15.4.2 Clinical Trial Registration..................................................................................47
15.4.3 Clinical Trial Results Disclosure ........................................................................48
15.5
Insurance and Compensation for Injury....................................................................48
16.0
REFERENCES..............................................................................................................49
LIST OF IN-TEXT FIGURES
Figure 6.a
Schematic of Study Design ................................................................................19
LIST OF APPENDICES
Appendix A
Schedule of Study Procedures............................................................................53
Appendix B
Responsibilities of the Investigator.....................................................................54
Appendix C
Elements of the Subject Informed Consent.........................................................55
Appendix D
Investigator Consent to Use of Personal Information..........................................58
Appendix E
Detailed Description of Amendments to Text.....................................................59

Study No. MDD-5003
Page 10 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
2.0
STUDY SUMMARY
Name of Sponsor(s):
Takeda US Medical Affairs
Compound:
Not applicable
Title of Protocol: A Single Center Pilot Study to Evaluate 
Real Time Passive and Active High-Frequency Cognitive 
and Mood Assessment Data in Major Depressive Disorder 
Using Digital Wearable Technology 
IND No.: Not Applicable
EudraCT No.:
Not Applicable
Study Number: MDD-5003
Phase: Phase 4
Study Design:
The study is a single-arm, unblinded, 6-week prospective observational feasibility study, designed to assess the 
feasibility and compliance with a novel method for assessing mood and cognition in subjects with major depressive 
disorder (MDD). The study assesses the feasibility of and compliance with cognitive and mood testing using wearable 
technology and the correlation of mood and cognition outcomes on wearable technology with traditional objective 
neuropsychological cognitive function tests and self-reported mood outcomes. Thirty subjects aged between 18 and 65 
years, inclusive, with mild-moderate depression prescribed second- or third-line antidepressant monotherapy will be 
recruited. Subjects will be provided with an Apple Watch on which brief cognitive and mood tests will be 
administered daily. Subjects will take part in up to 5 study visits, 1 in-person on-site visit, 3 web-based and 1 at home 
visit assessing performance on traditional objective neuropsychological cognitive function tests and self-reported 
measures of depression symptom severity and social function.
Coprimary Objectives:
To evaluate feasibility of and subject compliance with high-frequency testing of cognition and mood on wearable 
technology. Additionally to compare measures of mood and cognition on wearable technology against traditional 
objective neuropsychological cognitive function tests and self- reported measures of depression symptom severity 
outcome measures.
Subject Population: Subjects aged 18 to 65 years, inclusive, with MDD.
Number of Subjects:
30 subjects total 
Number of Sites: 
Estimated total: 1 site
Dose Level(s):
Not applicable
Route of Administration:
Not applicable
Duration of Treatment:
Not applicable
Period of Evaluation:
6 weeks
Main Criteria for Inclusion:

The subject is a man or woman, aged 18 to 65 years, inclusive, and able to read and understand English.

The subject suffers from MDD as the primary psychiatric diagnosis. 

The subject is currently being treated with an antidepressant (monotherapy).

The subject has scores on Patient Health Questionnaire-9 items (PHQ-9) ≥5 and PHQ-9 ≤15 at Screening.

In the opinion of the investigator, the subject is capable of understanding and complying with protocol 
requirements.

The subject signs and dates a written, informed consent form and any required privacy authorization prior to the 
initiation of any study procedures, after the nature of the study has been explained according to local regulatory 
requirements.

Study No. MDD-5003
Page 11 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Main Criteria for Exclusion:

The subject has any current psychiatric disorder other than MDD (except nonprimary concurrent anxiety), other 
illness or condition that may compromise the study in the opinion of the investigator.

The subject has a history of only responding to either combination or augmentation therapy in the current episode.

The subject is considered to be at imminent risk for hospitalization due to severe depression in the opinion of the 
investigator. Recent hospitalization due to MDD within 3 months prior to Screening is also exclusionary.

The subject has a significant risk of suicide according to the investigator’s clinical judgment or has made an actual 
suicide attempt in the previous 6 months prior to Screening.
Main Criteria for Evaluation and Analyses:
The coprimary endpoints for this study are feasibility and compliance with testing on a wearable and correlations 
between measures obtained from the wearable technology compared with traditional objective neuropsychological 
cognitive function tests and self-reported measures of depression symptom severity outcome measures.
Statistical Considerations:
The coprimary aim is assessed by evaluating the number of wearable cognitive and mood assessments completed for 
each study day by the subject, as a proportion of the assessments requested. 
Additionally the correlation between measures obtained on the wearable technology compared with traditional 
objective neuropsychological cognitive function tests and self-reported measures of depression symptom severity 
outcome measures will be assessed.
As this is a feasibility study, designed to guide future studies using this methodology, for the coprimary outcomes, 
inferential statistics will not be used, but the magnitude of correlations and rates of adherence will be described. 
Sample Size Justification:
Using a sample size of 30, will be able to estimate a compliance rate of 80% to within a 95% CI of ±12.8%. The 
proposed sample size also provides 80% power to detect correlations of r=0.5.

Study No. MDD-5003
Page 12 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
3.0
STUDY REFERENCE INFORMATION
3.1
Study-Related Responsibilities
The sponsor will perform all study-related activities with the exception of those identified in the 
Study-Related Responsibilities template. The identified vendors in the template for specific 
study-related activities will perform these activities in full or in partnership with the sponsor.
3.2
Coordinating Investigator
Takeda will select a Signatory Coordinating Investigator from the investigators who participate in 
the study. Selection criteria for this investigator will include significant knowledge of the study 
protocol, their expertise in the therapeutic area and the conduct of clinical research as well as study 
participation. The Signatory Coordinating Investigator will be required to review and sign the 
clinical study report and by doing so agrees that it accurately describes the results of the study.

Study No. MDD-5003
Page 13 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
3.3
List of Abbreviations
AE
adverse event
CANTAB
Cambridge Neuropsychological Test Automated Battery
CRF
case report form
DSM-5
Diagnostic and Statistical Manual of Mental Disorders, 5th Edition
ERT
Emotion Recognition Test
FAS
full analysis set
FDA
Food and Drug Administration
GCP
Good Clinical Practice
ICH
International Conference on Harmonisation
IEC
independent ethics committee
IRB
institutional review board
MDE
major depressive episode
MDD
major depressive disorder
PHQ-9
Patient Health Questionnaire—9 items
PPS
per protocol set
PRO
patient-reported outcomes
RVP
Rapid Visual Information Processing
SAE
serious adverse event
SSR
special situation report
SUSAR
suspected unexpected serious adverse reaction
SWM
Spatial Working Memory
3.4
Corporate Identification
TDC Japan
Takeda Development Center Japan
TDC Asia
Takeda Development Center Asia, Pte Ltd
TDC Europe
Takeda Development Centre Europe Ltd.
TDC Americas
Takeda Development Center Americas, Inc.
TDC
TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda
TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
CCI
CCI
CCI

Study No. MDD-5003
Page 14 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
4.0
INTRODUCTION
4.1
Background
Major depressive disorder (MDD) is a leading cause of disability. The 12-month prevalence of 
MDD is approximately 7%, with more women than men affected [1]. The World Health 
Organization classified the disorder as the leading cause of years lost due to disability globally [2]. 
It is thought that cognitive impairment contributes significantly to this burden, offering a clinically 
relevant target for intervention.
4.1.1
Cognitive Impairment in MDD
Cognitive symptoms of depression (eg, difficulty concentrating or making decisions) are 
recognized as a core feature in the Diagnostic and Statistical Manual of Mental Disorders, 5th 
Edition (DSM-5), and contribute to work-related disability and adverse psychosocial outcomes 
[3-9], beyond the impact of depressed mood. Cognitive deficits can be found in first-episode 
depression, and in recurrent depression both contribute to the risk of relapse, and worsen with 
repeated depressive episodes [10-14].
Cognition in depression is measured both through performance on objective cognitive tests and by 
patient-reported symptoms. The profile of cognitive impairment in depression is characterized by 
deficits in several domains, including processing speed, attention, executive function, and learning 
and memory [9,15-17]. However, there is poor correspondence between a patient’s objectively 
measured cognitive function and patients’ self-report [18,19], with the latter being affected by 
depressed mood. Therefore, both subjective and objective data need to be acquired as they provide 
complimentary clinically relevant information.
Cognitive dysfunction represents an underrecognized and undertreated aspect of depressive 
illness: when self-reported symptoms are examined, the majority of patients report impairment. In 
a prospective study of 267 subjects with MDD followed over 3 years while receiving treatment, 
the prevalence of symptoms of cognitive dysfunction was 94% during the acute phase of MDD and 
up to 44% during remission [13]. In a prospective, randomized, pragmatic clinical study of 
outpatients with nonpsychotic MDD (N=1426), the baseline prevalence of difficulty concentrating 
was 90%, with higher prevalence in those with repeated episodes [20]. On objective measurement 
using neuropsychological testing, cognitive dysfunction in depression is of moderate severity 
across multiple domains, with standardized effect sizes, ranging from 0.2 to 0.7 relative to 
unaffected controls [11,21-23]. There is increasing evidence that performance on standardized 
cognitive tests remains impaired even following remission of low mood in patients with MDD 
[12,21,24,25].
4.1.2
Functional Implications of Cognitive Dysfunction in MDD 
Both objectively and subjectively measured cognitive difficulties impact daily function in patients 
with MDD, affecting function in work, home, and social settings, contributing to the disability 
burden of this disease. A multinational epidemiological study of 21,000 subjects [26] reported a 

Study No. MDD-5003
Page 15 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
robust relationship between MDD and impaired home and occupational functioning. This was 
largely mediated by patient reported cognitive symptoms. Smaller studies have looked at the 
association between objectively measured cognitive function and functioning. Poorer objectively 
measured memory [27,28], attention, and executive function [18] have all been associated with 
impaired ability to perform activities of daily living in samples of individuals with MDD. 
Occupational performance is, perhaps unsurprisingly, associated with cognitive dysfunction 
across multiple cognitive domains [19,29,30]. Objective cognitive deficits are associated strongly 
to unemployment [19], and patient-reported cognitive symptoms impact on productivity and 
length of sick leave in a 2-year observational cohort study, even when controlling for depression 
severity [30]. Therefore, characterizing and treating these deficits has the potential to impact on 
functional outcomes and quality of life. 
4.1.3
Assessment of Cognition and Mood on Mobile and Wearable Technology in Patients 
With Depression
One of the key obstacles to targeting the cognitive symptoms of depression is the lack of 
awareness from clinicians and patients of the presence of such impairments, and the lack of readily 
available tools for performing such assessments away from the clinic. The development of such 
tools has the potential to support the treatment and remediation of cognitive deficits associated 
with MDD. Mobile applications to assess patient-reported outcomes (PROs) are becoming 
increasingly acceptable in the context of clinical research, and have been used to track changes in 
mood in patients with depression [31-33], and as part of randomized-controlled studies to evaluate 
treatment efficacy [34].
Wearable technology such as smart watches are a more recent development, and therefore there 
are fewer examples of active measurement of cognition and symptoms on these wearables, 
although assessments of activity data from wrist-worn accelerometers have been found to be 
related to mood in patients with depression [35]. 
A recent feasibility study used the Microsoft band wearable technology to deliver an n-back test. 
The n-back is a measure of cognition, which asks participants to monitor a series of items briefly 
one at a time (in this case symbols) to detect a match “n” items ago. This task is nominally a test of 
working memory, requiring storage encoding and updating of a short-term store, but has been 
found to relate to a broad range of other cognitive domains including attention and executive 
function. The task has been extensively used in neuroimaging studies, which have shown 
performance to be related to a broad network of brain areas including prefrontal cortex, parietal 
lobe, and hippocampus [36]. Functional magnetic resonance imaging studies in depressed patients 
have shown that subjects recruited more resources within this same neural network to maintain a 
similar level of performance as controls. Data from the wearable instance of the n-back showed 
significant correlations with cognitive performance measured using the Cambridge 
Neuropsychological Test Automated Battery (CANTAB) battery of tests [37], suggesting that this 
may be a meaningful way of assessing cognition, which can be applied in patients with depression 
to track cognition.

Study No. MDD-5003
Page 16 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
4.2
Rationale for the Proposed Study
Cognitive problems are common in major depression and are under recognized by both patients 
and clinicians. High-frequency, near-patient, cognitive testing provides the opportunity to detect 
and understand the pattern of cognitive symptoms, to maximize patient engagement with treatment 
and to inform clinicians regarding the severity, impact, and time course of cognitive deficits in 
patients with depression. The present study aims to assess the feasibility and compliance of an 
assessment of cognitive function and mood implemented on a smart watch in subjects with 
depression, with the goal of being as sensitive as the external traditional objective 
neuropsychological cognitive function tests and self-reported measures of depression symptom 
severity outcome measures) measures of cognition in detecting and understanding the change in 
cognitive function and the potential of developing a method for assessing cognition and mood in 
subjects undergoing treatment with antidepressant medication in clinical or research settings.
4.3
Benefit/Risk Profile 
Not applicable.

Study No. MDD-5003
Page 17 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
5.0
STUDY OBJECTIVES AND ENDPOINTS
5.1
Objectives
5.1.1
Coprimary Objectives
!
To evaluate feasibility of and subject compliance with high-frequency testing of cognition and 
mood on wearable technology.
!
To compare measures of mood and cognition on wearable technology against traditional 
objective neuropsychological cognitive function tests and self-reported measures of 
depression symptom severity outcome measures. 
5.1.2
Additional Objectives
!
!
5.2
Endpoints
5.2.1
Coprimary Endpoints
!
Compliance with daily wearable testing, defined as number of tests completed over the 6-week 
study period.
!
Correlations between measures of cognition on the wearable technology (n-back d’) and 
performance on the CANTAB tests. 
5.2.2
Additional Endpoints
!
!
!
!
CCI
CCI

Study No. MDD-5003
Page 18 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
6.0
STUDY DESIGN AND DESCRIPTION
6.1
Study Design
The study is a single-arm, unblinded, 6-week prospective observational feasibility study, designed 
to assess the feasibility and compliance with a novel method for assessing mood and cognition in 
subjects with MDD. The study assesses the feasibility of and compliance with cognitive and mood 
testing using wearable technology and the correlation of mood and cognition outcomes on 
wearable technology with traditional objective neuropsychological cognitive function tests and 
self-reported mood outcomes. Thirty subjects aged between 18 and 65 years, inclusive, with 
mild-moderate depression prescribed second- or third-line antidepressant monotherapy will be 
recruited. Thirty subjects will be provided with an Apple Watch on which brief cognitive and 
mood tests will be administered daily. All subjects will take part in up to 5 study visits, 1 in-person 
on-site visit, 3 web-based and 1 at home visit, assessing performance on traditional objective 
neuropsychological cognitive function tests and self-reported measures of depression symptom 
severity and social function. A schematic of the study design is included as Figure 6.a. A schedule 
of assessments is listed in Appendix A.

Study No. MDD-5003
Page 19 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Figure 6.a
Schematic of Study Design

Study No. MDD-5003
Page 20 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
6.2
Justification for Study Design, Dose, and Endpoints
The study population consists of patients with mild-moderate depression, aged between 18 and 
65 years, inclusive. The study is a single-arm, unblinded, prospective feasibility study, designed to 
assess the feasibility and compliance with, a novel method for assessing mood and cognition in 
subjects with MDD. The proposed sample size is 30 subjects. 
The wearable technology chosen for this study is the Apple Watch. This has a high-resolution 
display, which enables the presentation of stimuli and a touch screen for the collection of 
participant responses. The cognitive task employed on the wearable is the n-back test [38]. This 
task has been previously used in studies of daily cognitive testing over 100 study days in older 
adults and in a prior feasibility study on a wearable technology in healthy participants, where it 
was found to correlate with performance on CANTAB tasks of working memory, executive 
function, and processing speed [37,39]. On average, in this study participants completed 2 
assessments on the wearable each day, although the length of the study was shorter than in the 
current protocol at only 2 weeks. The length of the present study, over 6 weeks, corresponds to the 
time period over which response to antidepressant pharmacotherapy shows its efficacy in treating 
the mood symptoms of MDD. If the wearable technology assessments being developed are to be 
effective in monitoring changes to cognitive symptoms following treatment, it should be useable 
by patients over a similar time frame. 
The recruitment of subjects with mild-moderate depression represents the most common range of 
severity encountered in clinical practice. Participants with this degree of depression are likely to 
show cognitive deficits, and therefore provide an insight into performance and compliance with 
the study. The sample size selected is based on the compliance and magnitude of correlations 
observed in our previous research [37]. 
6.3
Premature Termination or Suspension of Study or Study Site
6.3.1
Criteria for Premature Termination or Suspension of the Study
The study will be completed as planned unless 1 or more of the following criteria are satisfied that 
require temporary suspension or early termination of the study.

New information or other evaluation regarding the safety or efficacy of the study product that 
indicates a change in the known risk/benefit profile for the product, such that the risk /benefit is 
no longer acceptable for subjects participating in the study.

Significant violation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary study objectives or compromises subject safety.
6.3.2
Criteria for Premature Termination or Suspension of Study Sites
A study site may be terminated prematurely or suspended if the site (including the investigator) is 
found in significant violation of GCP, protocol, or contractual agreement, is unable to ensure 
adequate performance of the study, or as otherwise permitted by the contractual agreement.

Study No. MDD-5003
Page 21 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
6.3.3
Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Site(s)
In the event that the sponsor, an institutional review board (IRB)/independent ethics committee 
(IEC) to terminate or suspend the study or the participation of a study site, a study-specific 
procedure for early termination or suspension will be provided by the sponsor; the procedure will 
be followed by applicable study sites during the course of termination or study suspension.

Study No. MDD-5003
Page 22 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
7.0
SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry criteria, including test results, need to be confirmed prior to study entry. 
7.1
Inclusion Criteria
Subject eligibility is determined according to the following criteria prior to entry into the study: 
1. The subject is a man or woman, aged 18 to 65 years, inclusive, and able to read and understand 
English.
2. The subject suffers from MDD as the primary psychiatric diagnosis. 
3. The subject is currently being treated with an antidepressant (monotherapy) 
4. The subject has scores on PHQ-9 ≥5 and PHQ-9 ≤15 at Screening.
5. In the opinion of the investigator, the subject is capable of understanding and complying with 
protocol requirements.
6.
The subject signs and dates a written, informed consent form and any required privacy 
authorization prior to the initiation of any study procedures, after the nature of the study has 
been explained according to local regulatory requirements (Appendix B).
7.2
Exclusion Criteria
1. The subject reports any current psychiatric disorder other than MDD (except nonprimary 
concurrent anxiety), other illness, or condition that may compromise the study in the opinion 
of the investigator.
2. The subject is not currently receiving an antidepressant at the time of Screening.
3. The subject is considered to be at imminent risk for hospitalization due to severe depression in 
the opinion of the investigator. The subject has been hospitalized due to MDD within 3 months 
prior to Screening.
4. The subject has a significant risk of suicide according to the investigator’s clinical judgment or 
has made an actual suicide attempt in the previous 6 months prior to Screening.
5. The subject has a history of only responding to either combination or augmentation therapy in 
the current episode.
6. The subject has received any investigational compound within 30 days prior to Screening or 5 
half-lives prior to Screening, whichever is longer.
7. The subject is currently participating in another clinical study. 
8. The subject has participated in 2 or more interventional clinical studies in the year prior to 
Screening, or has participated in a clinical study for a psychiatric condition that is exclusionary 
per this protocol.

Study No. MDD-5003
Page 23 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
9. The subject is an immediate family member, study site employee, or is in a dependent 
relationship with a study site employee who is involved in conduct of this study (eg, spouse, 
parent, child, sibling). 
10. The subject reports 1 or more of the following:
a) Current or history of: manic or hypomanic episode, schizophrenia or any other psychotic 
disorder, including schizoaffective disorder, major depression with psychotic features, 
bipolar depression with psychotic features, obsessive compulsive disorder, mental 
retardation, organic mental disorders, or mental disorders due to a general medical 
condition as defined in DSM-5.
b) Current diagnosis or history of alcohol or other substance abuse or dependence (excluding 
nicotine or caffeine). 
c) Presence or history of a clinically significant neurological disorder (including epilepsy).
d) Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, 
Huntington disease, etc).
7.3
Criteria for Discontinuation or Withdrawal of a Subject
The primary reason for discontinuation or withdrawal of the subject from the study should be 
recorded in the case report form (CRF) using the following categories. For screen failure subjects, 
refer to Section 9.1.9.
1. Serious prestudy event or serious adverse event (SAE). The subject has experienced a serious 
prestudy event or SAE that prevents full participation in the study or the subject is unwilling to
continue because of the serious prestudy event or SAE.
2. Significant protocol deviation. The discovery that the subject failed to meet protocol entry 
criteria or did not adhere to protocol requirements, and continued participation poses an 
unacceptable risk to the subject’s health.
3. Lost to follow-up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
documents.
4. Voluntary withdrawal. The subject (or subject’s legally acceptable representative) wishes to 
withdraw from the study. The reason for withdrawal, if provided, should be recorded in the 
CRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary underlying reason should be recorded (ie, withdrawal due to an 
AE should not be recorded in the “voluntary withdrawal” category. 
5. Study termination. The sponsor, IRB, IEC, or regulatory agency terminates the study.

Study No. MDD-5003
Page 24 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
6. Other.
Note: The specific reasons should be recorded in the “specify” field of the CRF.
7.4
Procedures for Discontinuation or Withdrawal of a Subject
The investigator may discontinue a subject’s study participation at any time during the study when 
the subject meets the study termination criteria described in Section 7.3. In addition, a subject may 
discontinue his or her participation without giving a reason at any time during the study. Should a 
subject’s participation be discontinued, the primary criterion for termination must be recorded by 
the investigator. In addition, efforts should be made to perform all procedures scheduled for the 
Early Termination Visit. Discontinued or withdrawn subjects will not be replaced.

Study No. MDD-5003
Page 25 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
8.0
CLINICAL STUDY MATERIAL MANAGEMENT
This section contains information regarding all materials provided directly by the sponsor, and/or 
sourced by other means, that are required by the study protocol, including important sections 
describing the management of study material.
8.1
Study Materials
8.1.1
Ancillary Materials
Subjects will be provided with an Apple Watch Series 1, a black sports band, and charging cable.
This is a wearable, paired with an iPhone, which contains a range of sensors, including 
accelerometers and heart rate sensors. The study software measuring cognition (n-back) and mood 
will be installed. Subjects will sign for the wearable at the start of the study, and return the 
wearable at the Final Visit or Early Termination Visit. Researchers will sign for the return of the 
wearable. 
8.1.2
Storage
Prior to subjects receiving the wearable technology they will be kept in an appropriate, 
limited-access, secure place until they are used or returned to the sponsor or designee.
8.1.3
Accountability and Return of Ancillary Materials
Apple watches will be counted and reconciled at the site before being returned to the supplier.
The investigator or designee must ensure that the sponsor-supplied Apple watches are used in 
accordance with the protocol and is provided only to subjects enrolled in the study. To document 
appropriate use of the Apple watch the investigator or designee must maintain records of all 
sponsor-supplied materials to the site, site inventory, dispensation and use by each subject, and 
return to the supplier.
Prior to site closure or at appropriate intervals, a representative from the sponsor or its designee 
may perform accountability and reconciliation before sponsor-supplied materials are returned to 
the supplier. The investigator or designee will retain a copy of the documentation regarding 
sponsor-supplied accountability, return, and originals will be sent to the sponsor or designee as 
applicable.

Study No. MDD-5003
Page 26 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
9.0
STUDY PLAN
9.1
Study Procedures
The following sections describe the study procedures and data to be collected. For each procedure, 
subjects are to be assessed by the same investigator or site personnel whenever possible. The 
Schedule of Study Procedures is located in Appendix A.
9.1.1
Informed Consent Procedure
The requirements of the informed consent are described in Section 15.2.
Informed consent must be obtained prior to the subject entering into the study, and before any 
protocol-directed procedures are performed. A unique subject identification number (subject 
number) will be assigned to each subject at the time that informed consent is obtained; this subject 
number will be used throughout the study.
9.1.2
Demographics, Medical History, and Medication History Procedure
Demographic information to be obtained will include age, as described by the subject at Screening. 
Medical history to be obtained will include determining whether the subject has any significant 
conditions or diseases relevant to the disease under study that resolved at or prior to signing of 
informed consent. Ongoing conditions are considered concurrent medical conditions (see 
Section 9.1.4). Medication history information to be obtained includes any medication relevant to 
eligibility criteria stopped at or within 6 months prior to signing of informed consent.
9.1.3
Documentation of Concomitant Medications
Concomitant medication is any drug given during the observational study period. These may be 
prescribed by a physician or obtained by the subject over the counter. Concomitant medication is 
not provided by the sponsor. At each study visit, subjects will be asked whether they have taken 
any medication (used from signing of informed consent through the end of the study), and all 
medication including vitamin supplements, over-the-counter medications, and oral herbal 
preparations, must be recorded in the CRF.
9.1.4
Documentation of Concurrent Medical Conditions
Concurrent medical conditions are those significant ongoing conditions or diseases that are present 
at signing of informed consent. The condition (ie, diagnosis) should be described.
9.1.5
Procedures for Clinical Laboratory Samples
Not applicable.

Study No. MDD-5003
Page 27 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
9.1.6
Contraception and Pregnancy Avoidance Procedure
There are no requirements for contraception or pregnancy avoidance. Subjects should follow the 
instruction according to label for their prescribed antidepressant.
9.1.7
Pregnancy
Women of childbearing potential may be included in this study.
9.1.8
Electrocardiogram Procedure 
Not applicable.
9.1.9
Documentation of Screen Failure
Investigators must account for all subjects who sign informed consent. If the subject is withdrawn 
at the Screening Visit after signing the informed consent, the investigator should complete the 
CRF.
The primary reason for screen failure is recorded in the CRF using the following categories:

Serious prestudy event/AE.

Did not meet inclusion criteria or did meet exclusion criteria, specify reason.

Significant protocol deviation.

Lost to follow-up.

Voluntary withdrawal, specify reason.

Study termination.
Subject identification numbers assigned to subjects who fail screening should not be reused.
9.1.10 Documentation of Study Entrance
Only subjects who meet all of the inclusion criteria and none of the exclusion criteria are eligible 
for entrance into the observational study period. If the subject is found to be not eligible for 
entrance, the investigator should record the primary reason for failure on the applicable CRF.
9.1.11 Wearable Technology Data 
Subjects will be given an Apple Watch on which cognitive assessment and mood assessment will 
be carried out. Subjects will be asked to wear the watch between 8 AM and 10 PM daily for the 
6-week study period. All subjects will be prompted to complete cognitive and mood assessments 
on 3 occasions across the day. Two occasions (morning and afternoon) will comprise assessment 
of cognition, and the final assessment in the evening will constitute a review of the day focusing on 
self-reported depressed mood. For all subjects, passive sensor data will also be acquired via the 
Apple Watch to assess physical activity.

Study No. MDD-5003
Page 28 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
9.1.11.1 Wearable Cognitive Assessment 
The 2-Back is a working memory test in which 30 symbols are presented visually. Subjects are 
asked to make a response when the symbol is the same as that presented 2 earlier. The load on 
working memory reflects the ordering, retention, updating, and manipulation of 2 symbols and 
consideration of the relationship to a third newly presented symbol, which could have been a target 
or a nontarget. From this test, latency and d’ measure accuracy, which is the ratio hits (correct 
detection of an n-back match) and false alarms (responding when no n-back match was present) 
are calculated.
9.1.11.2
9.1.11.3
 
9.1.12 Subject Self-Report Measures 
9.1.12.1
 
9.1.12.2 Perceived Deficits Questionnaire Attention/Concentration and Planning/Organization 
Subscore 
CCI
CCI
CCI
CCI
CCI
CCI
CCI

Study No. MDD-5003
Page 29 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
9.1.12.3
9.1.13 CANTAB Cognitive Assessments 
The CANTAB is a computer-based cognitive assessment system consisting of a battery of 
neuropsychological tests, tapping distinct cognitive domains. The tests to be used in the present 
study are described in Sections 9.1.13.1 to 9.1.13.3. The CANTAB Cognitive Assessments will be 
administered via the Cantab Connect web-based testing interface. Subjects will be sent a unique 
link to a secure web-page delivering the tests.
9.1.13.1 Emotion Recognition Test
The Emotion Recognition Test (ERT) measures emotion processing bias. This task briefly 
presents subjects with morphed composite faces representing faces showing emotions of different 
intensities, and asks them to detect the emotions presented. As the intensity of the emotion 
decreases, the ability of subjects to detect the portrayed emotion decreases. Outcomes are accuracy 
of responses for each emotional expression
9.1.13.2 Spatial Working Memory
CANTAB–Spatial Working Memory (SWM) assesses a subject’s retention of spatial information, 
ability to manipulate remembered items, and strategize. The subject is asked to find tokens in 
on-screen boxes and move them. Difficulty ranges from 4 to 8 box assessments, 2 trials for each 
assessment. Possible errors for each successful assessment: 4 box 0-38; 6 box 0-58; 8 box 0-78. 
Between Errors for N Boxes is the cumulative number of errors per each successful study. Total 
scores range from 0 to 175. Lower scores indicate better performance. Strategy score is the number 
of unique boxes the subject searched in the two 6 and 8 box trials. The 6 box trial scores ranges 
from 1 (1 box searched for all 6 tokens) to 6 (6 boxes searched for 6 tokens). The 8 box trial score 
ranges from 1 (1 box searched) to 8 (8 boxes searched for 8 tokens). The total of the 4 trial scores 
ranges from 4 to 28. A lower score indicates better performance.
CCI
CCI
CCI

Study No. MDD-5003
Page 30 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
9.1.13.3 The Rapid Visual Information Processing
The Rapid Visual Information Processing (RVP) test from the CANTAB test battery is a measure 
of sustained attention. A white box appears in the center of the computer screen, inside which 
digits, from 2 to 9, appear in a pseudo-random order, at the rate of 100 digits per minute. Subjects 
are requested to detect target sequences of digits (for example, 2-4-6, 3-5-7, 4-6-8) and to register 
responses using the press pad. The administration time is 10 minutes. The main outcome measure 
is A’: a signal detection measure of sensitivity to the target, regardless of response tendency 
(expected range is 0.00 to 1.00). Median latency: The median response latency during assessment 
sequence blocks where the subject responded correctly.
9.1.14 Semistructured Interviews
Semistructured interviews will be carried out by trained researchers, according to prespecified 
interview templates. Interviews will be digitally recorded and researchers will take notes to aid in 
the analysis and interpretation of the interviews as outlined in Section 13.1.5.
9.1.14.1 Study Entry Interview 
Short semistructured interviews will be carried out to explore a subject’s expectations around the 
assessments on the Apple Watch, their motivations for taking part, and their understanding of 
cognition and cognitive testing. 
9.1.14.2 End of Study Interview
A 90-minute semistructured interview done as home based visit will explore subject’s experience 
of assessment on the wearable technology over time, any changes in motivation and compliance, 
and the contextual factors that might have contributed to those changes. The purpose of the home 
visit is to explore in depth the factors that impact people’s compliance and motivation with 
high-frequency cognitive and mood testing. Since these visits will take place in the context of 
people’s use of the wearable and cognitive and mood assessments during the trial period, they will 
enable the researchers to draw on the range of these contextual elements during the 
semi-structured interview. As such, it will allow the researcher to observe qualitative issues that 
participants might not have deemed important, and as a result identify drivers or barriers that might 
otherwise be forgotten or missed outside of this real world setting.
9.2
Schedule of Observations and Procedures
The schedule for all study-related procedures for all evaluations is shown in Appendix A. 
Assessments should be completed at the designated visit/time point(s).
9.2.1
Screening 
Subjects will be screened within 21 days prior to Baseline. Procedures to be completed during the 
Screening Visit are detailed in Appendix A. Subjects will be screened in accordance with 

Study No. MDD-5003
Page 31 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
predefined inclusion and exclusion criteria as described in Section 7.0. See Section 9.1.9 for 
procedures for documenting screening failures.
Procedures to be completed at Screening include:
!
Informed consent.
!
Demographics, medical history, and medication history.
!
Concomitant medications. 
!
Concurrent medical conditions.
!
PHQ-9.
!
Serious prestudy event assessment.
9.2.2
Study Entrance (Visit 1)
Study entrance will take place on Day 1. The following procedures will be performed and 
documented at Study Entrance:
!
Assigned to study training on the use of the Apple Watch.
!
Training on the CANTAB tests.
!
Semistructured interview (Section 9.1.14.1).
!
Serious prestudy event assessment.
!
AE assessment.
If the subject has satisfied all of the inclusion criteria and none of the exclusion criteria the subject 
will be enrolled in the study The procedure for documenting screening failures is provided in 
Section 9.1.9.
9.2.3
Visits 2, 3, and 4
Subjects will log on to a secure study site hosting the CANTAB tests (Section 9.1.13) and 
self-report measures (ie, 
) (Section 9.1.12), which 
they will complete from home. Subjects will be instructed to select a quiet time to complete these 
tests when they will not be distracted. 
9.2.4
Phone Contacts: Reminder and Support Calls 
Reminder calls will be carried out during the study when the system detects that the cognitive task 
has not been completed in the same day or previous evening. The purpose is to check for the 
presence of technical difficulties with the watch or application software, or other barrier to 
compliance. The study also provides a support number for subjects to call should they experience 
any technical difficulties with the study hardware of software.
CCI

Study No. MDD-5003
Page 32 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Researchers will follow a script to facilitate the collection of relevant compliance information. 
Subject responses will be written down. Any unsolicited safety information described by the 
subject will be documented in the CRF and not written on the script used for the telephone call, and 
will be dealt with according to study AE reporting procedures.
9.2.5
Final Visit or Early Termination
The Final Visit will be a home based visit and will be performed on Study Day 44 (±3 days) or at 
the Early Termination Visit. The following procedures will be performed and documented:

Collection of the Apple Watch from subjects.

Semistructured interview (Section 9.1.14.2).

Concurrent medical conditions.

AE assessment.
9.2.6
Poststudy Care
The Apple Watch will not be available upon completion of the subject’s participation in the study. 
9.3
Biological Sample Retention and Destruction 
No biological samples will be collected. 

Study No. MDD-5003
Page 33 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
10.0
PRESTUDY EVENTS AND ADVERSE EVENTS
10.1
Definitions
10.1.1 Prestudy Event
A prestudy event is defined as any untoward medical occurrence in a clinical investigation subject 
who has signed informed consent to participate in a study but prior to study start; it does not 
necessarily have to have a causal relationship with study participation. In this study only prestudy 
events that meet serious criteria will be collected.
10.1.2 AEs
An AE is any untoward medical occurrence in a subject administered a medicinal product and 
which does not necessarily have to have a causal relationship with this treatment. An AE can 
therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, a new disease or worsening in severity or frequency of a concomitant disease, 
temporally associated with the use of a Takeda medicinal product, whether or not the event is 
considered causally related to the use of the Takeda product.
10.1.3 Special Situation Reports and Product Quality Issues
A special situation report (SSR) includes any of the following events:

Pregnancy: Any case in which a pregnancy patient is exposed to a Takeda product or in which 
a female patient or female partner of a male patient becomes pregnant following treatment with 
Takeda product. Exposure is considered either through maternal exposure or via semen 
following paternal exposure.

Breastfeeding: Infant exposure from breast milk.

Overdose: All information of any accidental or intentional overdose.

Drug abuse, misuse or medication error: All information on medicinal product abuse, misuse 
or medication error (potential or actual).

Suspected transmission of an infectious agent: All information on a suspected (in the sense of

confirmed or potential) transmission of an infectious agent by a medicinal product.

Lack of efficacy of Takeda product.

Occupational exposure.

Use outside the terms of the marketing authorisation, also known as “off-label”.

Use of falsified medicinal product.
A product quality issue refers to defects related to the safety, identity, strength, quality, or purity of 
the product or with the physical characteristics, packaging, labeling, or design of the product.

Study No. MDD-5003
Page 34 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
10.1.4
Serious Adverse Events
A serious adverse event (SAE) is defined as any untoward medical occurrence during the study:
1. Results in DEATH.
2. Is LIFE THREATENING.

The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event that hypothetically might have caused death 
if it were more severe.
3. Requires inpatient HOSPITALIZATION or prolongation of existing hospitalization.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5. Leads to a CONGENITAL ANOMALY/BIRTH DEFECT.
6. Is an IMPORTANT MEDICAL EVENT that satisfies any of the following:

May require intervention to prevent items 1 through 5 above.

May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalization.
Events that occur after the informed consent has been signed but before the study begins that fulfill 
1 or more of the serious criteria above are also to be considered SAEs and should be reported and 
followed up in the same manner (see Sections 10.2.3 and 10.3).
10.1.5
Severity of Prestudy Events and AEs
The different categories of intensity (severity) are characterized as follows:
Mild:
The event is transient and easily tolerated by the subject.
Moderate:
The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe:
The event causes considerable interference with the subject’s usual activities.
10.1.6
Relationship to Study Procedures
Relationship (causality) to study procedures should be determined for all SAEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibility that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as Not Related. 
10.1.7
Start Date
The start date of the SAE/prestudy event is the date that the first signs/symptoms were noted by the 
subject and/or investigator.

Study No. MDD-5003
Page 35 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
10.1.8
Stop Date 
The stop date of the SAE/prestudy event is the date at which the subject recovered, the event 
resolved but with sequelae or the subject died.
10.1.9
Frequency 
Episodic SAEs/prestudy events or those that occur repeatedly over a period of consecutive days 
are intermittent. All other events are continuous.
10.1.10 Outcome
!
Recovered/Resolved – Subject returned to first assessment status with respect to the 
SAE/prestudy event.
!
Recovering/Resolving – the intensity is lowered by 1 or more stages: the diagnosis or 
signs/symptoms has almost disappeared; the abnormal laboratory value improved, but has not 
returned to the normal range or to baseline; the subject died from a cause other than the 
particular SAE/prestudy event with the condition remaining “recovering/resolving”.
!
Not recovered/not resolved – there is no change in the diagnosis, signs or symptoms; the 
intensity of the diagnosis, signs/ symptoms or laboratory value on the last day of the observed 
study period has got worse than when it started; is an irreversible congenital anomaly; the 
subject died from another cause with the particular SAE/prestudy event state remaining “Not 
recovered/not resolved”.
!
Resolved with sequelae – the subject recovered from an acute SAE/prestudy event but was left 
with permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis.
!
Fatal – the SAEs/prestudy event which are considered as the cause of death. 
!
Unknown – the course of the SAE/prestudy event cannot be followed up due to hospital change 
or residence change at the end of the subject’s participation in the study.
10.2
Procedures 
10.2.1 Collection and Reporting of Spontaneous AEs, SSRs, and Product Quality Issues 
Related to a Takeda Product
If during the conduct of the study, a health care professional or patient spontaneously reports an 
AE, SSR, or product quality issue where the event/issue pertains to a Takeda product (or 
unbranded generic); such information should be reported to the sponsor. As such reports are 
spontaneously notified, causality of any AEs should be assumed unless there is evidence to the 
contrary.
Adverse events, special reporting situations or products complaints relating to any Takeda UK 
products received spontaneously must be reported to 
or by telephone 
PPD

Study No. MDD-5003
Page 36 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
(
) within 24 hours of awareness and no later than by the next working day. The 
preferred method for reporting is via email. If a report is received via telephone it should be backed 
up with an email.
10.2.2 Serious Prestudy Event and SAE Collection Period
Collection of SAEs will commence from the time the subject signs the informed consent to 
participate in the study and continue until the end of the study.
At each face to face (in-person) study visit, the investigator will assess whether any SAEs have 
occurred. A neutral question, such as “How have you been feeling since your last visit?” may be 
asked. Subjects may report spontaneous AEs occurring at any other time during the study. Subjects 
experiencing a serious prestudy event must be monitored until the symptoms subside or there is a 
satisfactory explanation for the change. Nonserious prestudy events, related or unrelated to the 
study procedure, need not to be followed-up for the purposes of the protocol.
All subjects experiencing SAEs, whether considered associated with the study procedures or not, 
must be monitored until the symptoms subside and or until there is a satisfactory explanation for 
the changes observed. All serious prestudy events and SAEs that occur during the study period will 
be documented in the CRF, whether or not the investigator concludes that the event is related to the 
study procedures. The following information will be documented for each event:
1. Event term.
2. Start and stop date.
3. Frequency.
4. Intensity.
5. Investigator’s opinion of the causal relationship to study procedure(s), including the details of 
the suspected procedure.
6. Outcome of event.
7. Seriousness.
10.2.3
Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE form must be completed, in English, and signed by the investigator immediately or 
within 24 hours of first onset or notification of the event. The information should be completed as 
fully as possible but contain, at a minimum:
A short description of the event and the reason why the event is categorized as serious.
!
Subject identification number.
!
Investigator’s name.
PPD

Study No. MDD-5003
Page 37 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL

Relationship to study procedure.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Section 1.1. 
Any SAE spontaneously reported to the investigator following the AE collection period should be 
reported to the sponsor if considered related to study participation.
Reporting of serious prestudy events will follow the procedure described for SAEs.
10.3
Follow-up of SAEs
If information not available at the time of the first report becomes available at a later date, the 
investigator should complete a follow-up SAE form (or provide other written documentation and 
fax it within 24 hours of receipt. Copies of any relevant data from the hospital notes (eg, 
electrocardiograms, laboratory tests, discharge summary, postmortem results) should be sent to 
the addressee, if requested.
All SAEs should be followed up until resolution or permanent outcome of the event. The timelines 
and procedure for follow-up reports are the same as those for the initial report.
10.3.1
Safety Reporting to Investigators, IRBs, and Regulatory Authorities
The sponsor is responsible for submission of AEs and SSRs to regulatory authorities in accordance 
with local reporting requirements or the sponsor’s postmarketing commitments.
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, including the European 
Medicines Agency, investigators and IRBs or IECs, as applicable. Relative to the first awareness 
of the event by/or further provision to the sponsor or sponsor’s designee, SUSARs will be 
submitted to the regulatory authorities as expedited report within 7 days for fatal and 
life-threatening events and 15 days for other serious events, unless otherwise required by national 
regulations. The sponsor will also prepare an expedited report for other safety issues where these 
might materially alter the current benefit-risk assessment or consider changes in overall conduct of
the trial. The study site also will forward a copy of all expedited reports to his or her IRB or IEC.

Study No. MDD-5003
Page 38 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
11.0
STUDY-SPECIFIC COMMITTEES
Not applicable

Study No. MDD-5003
Page 39 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
12.0
DATA HANDLING AND RECORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan
or equivalent.
12.1
CRFs (Paper)
Completed CRFs are required for each subject.
The study site will supply CRFs for use during the study. These forms are used to transmit the 
information collected in the performance of this study to the sponsor and regulatory authorities, as 
applicable. CRFs must be completed in English. All paper CRFs must be filled out legibly in black 
or blue ballpoint ink (use of black ink is preferred).
Corrections are to be made by making a single-line strikeout of the incorrect information and 
writing in the revisions. All corrections must be initialed and dated. Reasons for significant 
corrections should additionally be included. All new additions are to be made with the date and 
sign, or sign and seal affixed. Corrections to eCRFs will be made directly in the system, and an 
audit trail of changes will be maintained at the site.
The principal investigator must review the CRFs for completeness and accuracy and must sign and 
date the appropriate CRFs as indicated. Furthermore, the investigator must retain full 
responsibility for the accuracy and authenticity of all data entered on the CRFs.
After submission of the CRFs to the sponsor, any change of, modification of or addition to the data 
on CRFs should be made by the investigator with use of change and modification records of CRFs 
(Data Clarification Form). The principal investigator must review the Data Clarification Form for 
completeness and accuracy, and must sign, or sign and seal, and date the form.
After the lock of the study database, any change of, modification of or addition to the data on the 
CRFs should be made by the investigator with use of change and modification records of the 
CRFs. 
CRFs may be reviewed for completeness and acceptability at the study site during periodic visits 
by the sponsor or its designee, as applicable. The sponsor or its designee will be permitted to 
review the subject’s medical and hospital records pertinent to the study to ensure accuracy of the 
CRFs. The completed CRFs are the sole property of the sponsor and should not be made available 
in any form to third parties, except for authorized representatives of appropriate governmental 
health or regulatory authorities, without written permission of the sponsor.
12.2
Record Retention
The investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms), 
and copies of all paper CRFs and query responses to enable evaluations or audits from regulatory 

Study No. MDD-5003
Page 40 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
authorities, the sponsor or its designees. Any source documentation printed on degradable thermal 
sensitive paper should be photocopied by the site and filed with the original in the subject’s chart 
to ensure long term legibility. Furthermore, International Conference on Harmonisation (ICH) E6 
Section 4.9.5 requires the investigator to retain essential documents specified in ICH E6 
(Section 8) until at least 2 years after the last approval of a marketing application for a specified 
drug indication being investigated or, if an application is not approved, until at least 2 years after 
the investigation is discontinued and regulatory authorities are notified. In addition, ICH E6 
Section 4.9.5 states that the study records should be retained until an amount of time specified by 
applicable regulatory requirements or for a time specified in the study site agreement between the 
investigator and sponsor.
Refer to the study site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval from the sponsor before disposing of any 
such documents.

Study No. MDD-5003
Page 41 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
13.0
STATISTICAL METHODS
13.1
Statistical and Analytical Plans
A statistical analysis plan will be prepared and finalized prior to database lock. This document will 
provide further details regarding the definition of analysis variables and analysis methodology to 
address all study objectives. A data review may be conducted prior to database lock to assess 
completeness of the study database and appropriateness of the planned statistical methods.
13.1.1 Analysis Sets
The full analysis set (FAS) is defined as all subjects who completed the Study Entrance Visit and 
received a study wearable technology with at least 1 day of assessments completed. This will be 
the data set for primary analysis. In this study, 2 kinds of analysis sets are defined: FAS, and safety 
analysis set. The definition of each analysis set will be described in the Handling Rules for 
Analysis Data or equivalent.
The safety set will include all subjects who were enrolled and completed the Study Entrance Visit. 
It is likely that the safety set will be the same as the FAS.
The sponsor will verify the validity of the definitions of the analysis sets as well as the rules for 
handling data, with consulting a medical expert as needed. If necessary, the Handling Rules for 
Analysis Data will be supplemented with new handling rules that were not discussed at the 
planning stage. The Handling Rules or equivalent for Analysis Data must be finalized prior to 
database lock.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Summary statistics (mean, SD, median, minimum, and maximum) for age, length of major 
depressive episode (MDE), number of prior MDEs, scores on PROs (
 
), scores on CANTAB cognitive test measures at enrollment will be calculated. 
Distributions of subjects by sex, and antidepressant class may be summarized if applicable. 
Demography tables will be presented for the all enrolled set and the per protocol set. Detailed 
subject listings will be located in the appendices.
13.1.3 Analysis of Wearable Technology Data Collection Compliance (Coprimary Aim)
This is a coprimary study endpoint, and will be analyzed by assessing the number of wearable
cognitive and mood assessments completed for each study day by the subject, as a proportion of 
the assessments requested. For each subject the percentage of study wearable assessments 
completed will be calculated and reported in tables overall and as a function of study day.
13.1.4 Analysis of Validity of Wearable and Mood Testing (Coprimary Aim)
This corresponds to the other coprimary aim of the study. Individual subject data on the wearable 
n-back cognitive test will be analyzed using a longitudinal nonlinear mixed model approach, 
CCI

Study No. MDD-5003
Page 42 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
which characterizes subject performance as a combination of an intercept and a slope, representing 
their overall ability and a learning effect, thereby reducing the dimensionality of the cognitive 
data. These derived cognitive performance parameters from the n-back will be correlated with 
performance on CANTAB measures of working memory (SWM), attention and concentration 
(RVP), and executive function (CANTAB SWM Strategy and One Touch Stockings) and 
, using a Pearson correlation coefficient, or 
nonparametric equivalent, depending on the observed distribution of data. These are the cognitive 
domains believed to be assessed by the n-back test. 
coefficients observed, rather than significance levels. No inferential statistical tests will be carried 
out, and therefore no adjustment for multiple comparisons is required. 
13.1.5 Qualitative Analysis
Qualitative assessment of factors relating to compliance will be obtained from the examination of 
themes emerging from 3 sources: 
1. Semistructured study entry interviews (Section 9.1.14.1 Study Day 1) focusing on subject’s 
expectations, motivation, and understanding around cognitive testing and technology. 
2. Study technical support queries and logs of within-study subject interactions from phone 
contacts (Section 9.2.4)
3. Semistructured end of study interviews (Section 9.1.14.2 Final Visit, Study Day 44) exploring 
subjects’ experience of the application over time, any changes in motivation and compliance, 
and the contextual factors that might have contributed to those changes.
Interpretative Phenomenological Analysis will be used to analyze the qualitative data. To increase 
the rigor and validity of the analysis, and as a form of triangulation, the analysis will be conducted 
by 3 members of the research team (the lead qualitative researcher and 2 others). Analysis will 
involve 2 stages: 
1. Data management, which will include: 
a) Familiarization with the data, reading notes, and/or listening to the audio dialogue in order 
to extract main themes and ideas. 
b) Thematic framework development, identifying the key issues and concepts present in the 
data and creating themes both inductively, based on the data, and deductively, based on the 
research questions. 
2. Interpretation stage, which will include focused defining the main concepts and mapping the 
ways in which different parts of the data are related to each other.
CCI
CCI

Study No. MDD-5003
Page 43 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
13.1.6 Safety Analysis
AEs will be summarized using the safety set. No statistical testing or inferential statistics will be 
generated. Data will be summarized using preferred term and primary system organ class.
13.2
Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3
Determination of Sample Size
The proposed sample size of 30 is commensurate with usual practice for feasibility studies [40]. 
Using a sample size of 30, will be able to estimate a compliance rate of 80% to within a 95% CI of 
±12.8%. The proposed sample size also provides 80% power to detect correlations of r=0.5, as per 
the secondary outcomes. 

Study No. MDD-5003
Page 44 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
14.0
QUALITY CONTROL AND QUALITY ASSURANCE
14.1
Study-Site Monitoring Visits
Monitoring visits to the study site may be made periodically during the study to ensure that all 
aspects of the protocol are followed. Source documents may be reviewed for verification of data 
recorded on the CRFs. Source documents are defined as original documents, data, and records. 
The investigator and the study site guarantee access to source documents by the sponsor or its 
designee (contract research organization) and by the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or sponsor’s 
designee (as long as blinding is not jeopardized), including but not limited to the Investigator’s 
Binder, subject medical records, informed consent documentation, documentation of subject 
authorization to use personal health information (if separate from the informed consent forms), 
and review of CRFs and associated source documents. It is important that the investigator and 
other study personnel are available during the monitoring visits and that sufficient time is devoted 
to the process.
14.2
Protocol Deviations
The investigator should not deviate from the protocol, except where necessary to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviation from protocol-specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exemptions (a prospectively approved deviation) from the inclusion or exclusion criteria.
The site should document all protocol deviations in the subject’s source documents. In the event of 
a significant deviation, the site should notify the sponsor or its designee (and IRB or EC, as 
required). Significant deviations include, but are not limited to, those that involve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviation Form should be completed by the site and signed by the sponsor 
or designee for any significant deviation from the protocol.
14.3
Quality Assurance Audits and Regulatory Agency Inspections
The study site also may be subject to quality assurance audits by the sponsor or designees. In this 
circumstance, the sponsor-designated auditor will contact the site in advance to arrange an 
auditing visit. The auditor may ask to visit the facilities where laboratory samples are collected, 
where the medication is stored and prepared, and any other facility used during the study. In 
addition, there is the possibility that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the Food and Drug Administration [FDA], the United Kingdom 
Medicines and Healthcare products Regulatory Agency, the Pharmaceuticals and Medical Devices 
Agency of Japan). If the study site is contacted for an inspection by a regulatory body, the sponsor 
should be notified immediately. The investigator and guarantee access for quality assurance 
auditors to all study documents as described in Section 14.1.

Study No. MDD-5003
Page 45 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
15.0
ETHICAL ASPECTS OF THE STUDY
This study will be conducted with the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the ICH Harmonized Tripartite Guideline for GCP. The investigator will conduct the 
study according to applicable local regulatory requirements and align his or her conduct in 
accordance with the “Responsibilities of the Investigator” that are listed in Appendix B. The 
principles of Helsinki are addressed through the protocol and through appendices containing 
requirements for informed consent and investigator responsibilities.
15.1
IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable local requirements of each 
participating region. The sponsor or designee will require documentation noting all names and 
titles of members who make up the respective IRB or IEC. If any member of the IRB or IEC has 
direct participation in this study, written notification regarding his or her abstinence from voting 
must also be obtained. 
The sponsor or designee will supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, a copy of the informed consent form, 
and, if applicable, subject recruitment materials and/or advertisements and other documents 
required by all applicable laws and regulations, must be submitted to a central or local IRB or IEC
for approval. The IRB’s or IEC’s written approval of the protocol and subject informed consent 
must be obtained and submitted to the sponsor or designee before commencement of the study.
The IRB or IEC approval must refer to the study by exact protocol title, number, and version date; 
identify versions of other documents (eg, informed consent form) reviewed; and state the approval 
date. The sponsor will notify site once the sponsor has confirmed the adequacy of site regulatory 
documentation and, when applicable, the sponsor has received permission from competent 
authority to begin the study. Until the site receives notification no protocol activities, including 
screening may occur.
Study sites must adhere to all requirements stipulated by their respective IRB or IEC. This may 
include notification to the IRB or IEC regarding protocol amendments, updates to the informed 
consent form, recruitment materials intended for viewing by subjects, local safety reporting 
requirements, reports and updates regarding the ongoing review of the study at intervals specified 
by the respective IRB or IEC, and submission of the investigator’s final status report to IRB or 
IEC. All IRB and IEC approvals and relevant documentation for these items must be provided to 
the sponsor or its designee.
Subject incentives should not exert undue influence for participation. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
15.2
Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 

Study No. MDD-5003
Page 46 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
applicable laws and regulations. The informed consent form, subject authorization form (if 
applicable), and subject information sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclosures of the subject’s personal and personal health information for purposes of 
conducting the study. The informed consent form and the subject information sheet (if applicable) 
further explain the nature of the study, its objectives, and potential risks and benefits, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any time without giving a reason and 
without prejudice to his or her further medical care.
The investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and if applicable, the subject authorization form. The informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form, subject authorization form (if applicable), and subject information 
sheet (if applicable) must be written in a language fully comprehensible to the prospective subject. 
It is the responsibility of the investigator to explain the detailed elements of the informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. 
The subject must be given ample opportunity to: (1) inquire about details of the study and (2) 
decide whether or not to participate in the study. If the subject, or the subject’s legally acceptable 
representative, determines he or she will participate in the study, then the informed consent form 
and subject authorization form (if applicable) must be signed and dated by the subject, or the 
subject’s legally acceptable representative, at the time of consent and prior to the subject entering 
into the study. The subject or the subject’s legally acceptable representative should be instructed to 
sign using their legal names, not nicknames, using blue or black ballpoint ink. The investigator 
must also sign and date the informed consent form and subject authorization (if applicable) at the 
time of consent and prior to subject entering into the study.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject information sheet (if applicable) will be stored in the investigator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization form 
(if applicable), and subject information sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a copy of the revised informed consent form.
15.3
Subject Confidentiality
The sponsor and designees affirm and uphold the principle of the subject’s right to protection 
against invasion of privacy. Throughout this study, a subject’s source data will only be linked to 

Study No. MDD-5003
Page 47 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
the sponsor’s clinical trial database or documentation via a subject identification number. As 
permitted by all applicable laws and regulations, limited subject attributes, such as sex, age, or date 
of birth may be used to verify the subject and accuracy of the subject’s unique identification 
number.
To comply with ICH Guidelines for GCP and to verify compliance with this protocol, the sponsor 
requires the investigator to permit the monitor or the sponsor’s designee, representatives from any 
regulatory authority (eg, FDA, Medicines and Healthcare products Regulatory Agency, 
Pharmaceuticals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
documents), including, but not limited to, laboratory test result reports, electrocardiogram reports, 
admission and discharge summaries for hospital admissions occurring during a subject’s study 
participation, and autopsy reports. Access to a subject’s original medical records requires the 
specific authorization of the subject as part of the informed consent process (see Section 15.2).
Copies of any subject source documents that are provided to the sponsor must have certain 
personally identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s CRF).
15.4
Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with complete test results and all data derived by 
the investigator from the study. During and after the study, only the sponsor may make study 
information available to other study investigators or to regulatory agencies, except as required by 
law or regulation. Except as otherwise allowable in the study site agreement, any public disclosure 
(including publicly accessible websites) related to the protocol or study results, other than study 
recruitment materials and/or advertisements, is the sole responsibility of the sponsor.
15.4.2 Clinical Trial Registration
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulations and guidance, Takeda will, at a minimum register all 
interventional clinical trials it sponsors anywhere in the world on ClinicalTrials.gov and/or other 
publicly accessible websites before start of study, as defined in Takeda Policy/Standard. Takeda 
contact information, along with investigator’s city, country, and recruiting status will be registered 
and available for public viewing. 
For some registries, Takeda will assist callers in locating study sites closest to their homes by 
providing the investigator name, address, and phone number to the callers requesting trial 
information. Once subjects receive investigator contact information, they may call the site 
requesting enrollment into the trial. The investigative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks additional 
questions beyond the topic of trial enrollment, they should be referred to the sponsor.

Study No. MDD-5003
Page 48 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Any investigator who objects to the sponsor providing this information to callers must provide the 
sponsor with a written notice requesting that their information not be listed on the registry site 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trials on ClinicalTrials.gov and/or other publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulations.
15.5
Insurance and Compensation for Injury
Each subject in the study must be insured in accordance with the regulations applicable to the site 
where the subject is participating. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study insurance against the risk of injury to study subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subject compensation and treatment for 
injury. If the investigator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.

Study No. MDD-5003
Page 49 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
16.0
REFERENCES
1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology 
of major depressive disorder: results from the National Comorbidity Survey Replication 
(NCS-R). JAMA 2003;289(23):3095-105.
2. World Health Organization (WHO). The Global Burden of Disease: 2004 Update. Published 
2008. Accessed 07 October 2014. Available at: 
http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf?ua=
1.
3. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major 
depressive disorder. Psychiatry Res 2006;145(1):39-48.
4. Evans VC, Iverson GL, Yatham LN, Lam RW. The relationship between neurocognitive and 
psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry 
2014;75(12):1359-70.
5. Evans VC, Chan SS, Iverson GL, Bond DJ, Yatham LN, Lam RW. Systematic review of 
neurocognition and occupational functioning in major depressive disorder. Neuropsychiatry 
2013;3(1):97-105.
6. Zajecka JM. Residual symptoms and relapse: mood, cognitive symptoms, and sleep 
disturbances. J Clin Psychiatry 2013;74 Suppl 2:9-13.
7. Bortolato B, Carvalho AF, McIntyre RS. Cognitive dysfunction in major depressive disorder: a 
state-of-the-art clinical review. CNS Neurol Disord Drug Targets 2014;13(10):1804-18.
8. Trivedi MH, Greer TL. Cognitive dysfunction in unipolar depression: Implications for 
treatment. J Affect Disord 2014;152-154:19-27.
9. Hammar A, Ardal G. Cognitive functioning in major depression--a summary. Front Hum 
Neurosci 2009;3:26.
10. Weisenbach SL, Boore LA, Kales HC. Depression and cognitive impairment in older adults. 
Curr Psychiatry Rep 2012;14(4):280-8.
11. Lee RS, Hermens DF, Porter MA, Redoblado-Hodge MA. A meta-analysis of cognitive 
deficits in first-episode Major Depressive Disorder. J Affect Disord 2012;140(2):113-24.
12. Hasselbalch BJ, Knorr U, Kessing LV. Cognitive impairment in the remitted state of unipolar 
depressive disorder: a systematic review. J Affect Disord 2011;134(1-3):20-31.
13. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during 
depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 
2011;41(6):1165-74.
14. Basso MR, Bornstein RA. Relative memory deficits in recurrent versus first-episode major 
depression on a word-list learning task. Neuropsychology 1999;13(4):557-63.

Study No. MDD-5003
Page 50 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
15. National Academies of Sciences/Engineering/Medicine. Enabling Discovery, Development, 
and Translation of Treatments for Cognitive Dysfunction in Depression: Workshop Summary. 
Washington, DC: The National Academies Press; 2015.
16. McClintock SM, Husain MM, Greer TL, Cullum CM. Association between depression 
severity and neurocognitive function in major depressive disorder: a review and synthesis. 
Neuropsychology 2010;24(1):9-34.
17. Porter RJ, Bourke C, Gallagher P. Neuropsychological impairment in major depression: its 
nature, origin and clinical significance. Aust N Z J Psychiatry 2007;41(2):115-28.
18. Gupta M, Holshausen K, Best MW, Jokic R, Milev R, Bernard T, et al. Relationships among 
neurocognition, symptoms, and functioning in treatment-resistant depression. Arch Clin 
Neuropsychol 2013;28(3):272-81.
19. Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. The role of cognitive 
impairment in general functioning in major depression. Psychiatry Res 2010;176(2-3):183-9.
20. Hollon SD, Shelton RC, Wisniewski S, Warden D, Biggs MM, Friedman ES, et al. Presenting 
characteristics of depressed outpatients as a function of recurrence: preliminary findings from 
the STAR*D clinical trial. J Psychiatr Res 2006;40(1):59-69.
21. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a 
systematic review and meta-analysis. Psychol Med 2014;44(10):2029-40.
22. Rund BR, Sundet K, Asbjornsen A, Egeland J, Landro NI, Lund A, et al. Neuropsychological 
test profiles in schizophrenia and non-psychotic depression. Acta Psychiatr Scand 
2006;113(4):350-9.
23. Snyder HR. Major depressive disorder is associated with broad impairments on 
neuropsychological measures of executive function: a meta-analysis and review. Psychol Bull 
2013;139(1):81-132.
24. Smith DJ, Muir WJ, Blackwood DH. Neurocognitive impairment in euthymic young adults 
with bipolar spectrum disorder and recurrent major depressive disorder. Bipolar Disord 
2006;8(1):40-6.
25. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive 
disorder: a meta-analysis. Psychol Med 2013;43(10):2017-26.
26. Buist-Bouwman MA, Ormel J, de Graaf R, de Jonge P, van Sonderen E, Alonso J, et al. 
Mediators of the association between depression and role functioning. Acta Psychiatr Scand 
2008;118(6):451-8.
27. Naismith SL, Longley WA, Scott EM, Hickie IB. Disability in major depression related to 
self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry 
2007;7:32.
28. McCall WV, Dunn AG. Cognitive deficits are associated with functional impairment in 
severely depressed patients. Psychiatry Res 2003;121(2):179-84.

Study No. MDD-5003
Page 51 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
29. Godard J, Grondin S, Baruch P, Lafleur MF. Psychosocial and neurocognitive profiles in 
depressed patients with major depressive disorder and bipolar disorder. Psychiatry Res 
2011;190(2-3):244-52.
30. Saragoussi D, Haro JM, Boulenger JP, Jönsson B, Knapp M, Caillou H, et al. Patient-Reported 
Cognitive Dysfunction Negatively Impacts Functioning in Patients with Major Depressive 
Disorder – Preliminary Findings from the Perform Study. Value in Health 
2013;16(7):A543-A4.
31. Kim J, Lim S, Min YH, Shin YW, Lee B, Sohn G, et al. Depression Screening Using Daily 
Mental-Health Ratings from a Smartphone Application for Breast Cancer Patients. J Med 
Internet Res 2016;18(8):e216.
32. Torous J, Staples P, Shanahan M, Lin C, Peck P, Keshavan M, et al. Utilizing a Personal 
Smartphone Custom App to Assess the Patient Health Questionnaire-9 (PHQ-9) Depressive 
Symptoms in Patients With Major Depressive Disorder. JMIR Ment Health 2015;2(1):e8.
33. Tsanas A, Saunders KE, Bilderbeck AC, Palmius N, Osipov M, Clifford GD, et al. Daily 
longitudinal self-monitoring of mood variability in bipolar disorder and borderline personality 
disorder. J Affect Disord 2016;205:225-33.
34. Anguera JA, Jordan JT, Castaneda D, Gazzaley A, Arean PA. Conducting a fully mobile and 
randomised clinical trial for depression: access, engagement and expense. BMJ Innov 
2016;2(1):14-21.
35. Kim J, Nakamura T, Kikuchi H, Yoshiuchi K, Sasaki T, Yamamoto Y. Covariation of 
depressive mood and spontaneous physical activity in major depressive disorder: toward 
continuous monitoring of depressive mood. IEEE J Biomed Health Inform 
2015;19(4):1347-55.
36. Owen AM, McMillan KM, Laird AR, Bullmore E. N-back working memory paradigm: a 
meta-analysis of normative functional neuroimaging studies. Hum Brain Mapp 
2005;25(1):46-59.
37. Cormack FK, Taptiklis N, Barnett JH, King J, Fenhert B. High-frequency monitoring of 
cognition mood and behavior using commercially available wearable devices. Alzheimers 
Dement 2016;12(7 Suppl):P159. 2016 Alzheimer's Association International Conference, 
Poster TD-P-017.
38. Awh E, Jonides J, Smith EE, Schumacher EH, Koeppe RA, Katz S. Dissociation of storage and 
rehearsal in verbal working memory: evidence from positron emission tomography. Psychol 
Sci 1996;7(1):25-31.
39. Brose A, Schmiedek F, Lovden M, Lindenberger U. Daily variability in working memory is 
coupled with negative affect: the role of attention and motivation. Emotion 2012;12(3):605-17.

Study No. MDD-5003
Page 52 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
40. Billingham SA, Whitehead AL, Julious SA. An audit of sample sizes for pilot and feasibility 
trials being undertaken in the United Kingdom registered in the United Kingdom Clinical 
Research Network database. BMC Med Res Methodol 2013;13:104.

Study No. MDD-5003
Page 53 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Appendix A
Schedule of Study Procedures
Screening
Baseline 
Study Day/Week:
Days -21 to 
-1
Day 1 
(In-person)
(a)
Day 2
(Web-based)
Week 3
(Web-based)
Week 6 
(Web-based)
Final Visit or 
Early 
Termination 
Visit (In-
person Home 
Based)
Week 6 (b)
Visit Windows (Days):
1 to 2
18 to 24
40 to 46
41 to 47
Visit Number:
-1
1
2
3
4
5
Informed consent
X
Inclusion/exclusion criteria
X
X
Demographics and medical history
X
Medication history
X
Concomitant medications
X
X
X
Concurrent medical conditions
X
X
CANTAB cognitive testing 
X
X
X
Semistructured interview
X
X
Provide subjects with study wearable 
technology and training
X
Wearable cognitive and mood assessment 
Wearable activity measurement (includes 
HR)
Return of study wearable 
X
Serious Prestudy event assessment
X
X
AE assessment
X
X
X
X
X
(a) In-person on site visit.
(b) Conduct face to face (in person-home based) Final Visit procedures for subjects discontinued early per Section 7.4. The end of study is 
defined as the date of the last visit (Day 44) of the last subject undergoing the study unless the study is stopped earlier by the sponsor.
CCI
CCI
CCI

Study No. MDD-5003
Page 54 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Appendix B
Responsibilities of the Investigator
Clinical research studies sponsored by the sponsor are subject to ICH GCP and all the applicable 
local laws and regulations. The investigator agrees to assume the following responsibilities:
1. Conduct the study in accordance with the protocol.
2. Personally conduct or supervise the staff who will assist in the protocol.
3. Ensure that study related procedures, including study specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of written 
approval from relevant governing bodies/authorities.
4. Ensure that all colleagues and employees assisting in the conduct of the study are informed of 
these obligations.
5. Secure prior approval of the study and any changes by an appropriate IRB/IEC that conform to 
ICH, and local regulatory requirements.
6. Ensure that the IRB/IEC will be responsible for initial review, continuing review, and approval 
of the protocol. Promptly report to the IRB/IEC all changes in research activity and all 
anticipated risks to subjects. Make at least yearly reports on the progress of the study to the 
IRB/IEC, and issue a final report within 3 months of study completion.
7. Ensure that requirements for informed consent, as outlined in ICH and local regulations, are 
met.
8. Obtain valid informed consent from each subject who participates in the study, and document 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
version approved by the IRB/IEC. Each informed consent form should contain a subject 
authorization section that describes the uses and disclosures of a subject’s personal 
information (including personal health information) that will take place in connection with the 
study. If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
9. Prepare and maintain adequate case histories of all persons entered into the study, including 
CRFs, hospital records, laboratory results, etc, and maintain these data for a minimum of 
2 years following notification by the sponsor that all investigations have been discontinued or 
that the regulatory authority has approved the marketing application. The investigator should 
contact and receive written approval from the sponsor before disposing of any such 
documents.
10. Allow possible inspection and copying by the regulatory authority of GCP-specified essential 
documents.
11. Report adverse reactions to the sponsor promptly. In the event of an SAE, notify the sponsor 
within 24 hours.

Study No. MDD-5003
Page 55 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Appendix C
Elements of the Subject Informed Consent 
In seeking informed consent, the following information shall be provided to each subject:
1. A statement that the study involves research.
2. An explanation of the purposes of the research.
3. The expected duration of the subject’s participation.
4. A description of the procedures to be followed, including invasive procedures.
5. The identification of any procedures that are experimental.
6. The estimated number of subjects involved in the study.
7. A description of the subject’s responsibilities.
8. A description of the conduct of the study.
9. A statement describing the treatment(s) and the probability for random assignment to each 
treatment.
10. A description of the possible side effects of the treatment that the subject may receive.
11. A description of any reasonably foreseeable risks or discomforts to the subject and, when 
applicable, to an embryo, fetus, or nursing infant.
12. A description of any benefits to the subject or to others that reasonably may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13. Disclosures of appropriate alternative procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potential risks and benefits.
14. A statement describing the extent to which confidentiality of records identifying the subject 
will be maintained, and a note of the possibility that regulatory agencies, auditor(s), IRB/IEC, 
and the monitor may inspect the records. By signing a written informed consent form, the 
subject or the subject’s legally acceptable representative is authorizing such access.
15. For research involving more than minimal risk, an explanation as to whether any compensation 
and an explanation as to whether any medical treatments are available if injury occurs and, if 
so, what they consist of or where further information may be obtained.
16. The anticipated prorated payment(s), if any, to the subject for participating in the study.
17. The anticipated expenses, if any, to the subject for participating in the study.
18. An explanation of whom to contact for answers to pertinent questions about the research 
(investigator), subject’s rights, and IRB/IEC and whom to contact in the event of a 
research-related injury to the subject.

Study No. MDD-5003
Page 56 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
19. A statement that participation is voluntary, that refusal to participate will involve no penalty or 
loss of benefits to which the subject otherwise is entitled, and that the subject may discontinue 
participation at any time without penalty or loss of benefits to which the subject is otherwise 
entitled.
20. The consequences of a subject’s decision to withdraw from the research and procedures for 
orderly termination of participation by the subject.
21. A statement that the subject will be informed in a timely manner if information becomes 
available that may be relevant to the subject’s willingness to continue participation in the 
study.
22. A statement that results of pharmacogenomic analysis will not be disclosed to an individual, 
unless prevailing laws require the sponsor to do so.
23. The foreseeable circumstances or reasons under which the subject’s participation in the study 
may be terminated.
24. A written subject authorization (either contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s personal information (including personal health information) for 
purposes of conducting the study. The subject authorization must contain the following 
statements regarding the uses and disclosures of the subject’s personal information:
a) that personal information (including personal health information) may be processed by or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) Takeda, its affiliates, and 
licensing partners; (2) business partners assisting Takeda, its affiliates, and licensing 
partners; (3) regulatory agencies and other health authorities; and (4) IRBs/IECs;
b) it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country; 
however, Takeda will make every effort to keep your personal information confidential, 
and your name will not be disclosed outside the clinic unless required by law;
c) that personal information (including personal health information) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the
developing a better understanding of disease, studying other therapies for patients, and 
improving the efficiency of future clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study to the extent that 
the restricted use or disclosure of such information may impact the scientific integrity of 
the research; and
e) that the subject’s identity will remain confidential in the event that study results are 
published.

Study No. MDD-5003
Page 57 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
25. A statement that clinical trial information from this trial will be publicly disclosed in a publicly 
accessible website, such as ClinicalTrials.gov.

Study No. MDD-5003
Page 58 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Appendix D
Investigator Consent to Use of Personal Information
Takeda will collect and retain personal information of the investigator, including his or her name, 
address, and other personally identifiable information. In addition, investigator’s personal 
information may be transferred to other parties located in countries throughout the world (e.g., the 
United Kingdom, United States, and Japan), including the following:

Takeda, its affiliates, and licensing partners.

Business partners assisting Takeda, its affiliates, and licensing partners.

Regulatory agencies and other health authorities.

IRBs and IECs.
Investigator’s personal information may be retained, processed, and transferred by Takeda and 
these other parties for research purposes including the following:

Assessment of the suitability of investigator for the study and/or other clinical studies.

Management, monitoring, inspection, and audit of the study.

Analysis, review, and verification of the study results.

Safety reporting and pharmacovigilance relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to the study.

Preparation and submission of regulatory filings, correspondence, and communications to 
regulatory agencies relating to other medications used in other clinical studies. Inspections and 
investigations by regulatory authorities relating to the study.

Self-inspection and internal audit within Takeda, its affiliates, and licensing partners.

Archiving and audit of study records.

Posting investigator site contact information, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Investigator’s personal information may be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in investigator’s own 
country.
Investigator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.

Study No. MDD-5003
Page 59 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Appendix E
Detailed Description of Amendments to Text
This document describes changes in reference to Protocol Incorporating Amendment No. 01.
Pages 10 and 22, Sections 2.0, 7.1, and 7.2
Existing Text
Inclusion Criteria
3. The subject has been treated previously with at least 1 antidepressant (monotherapy) and has 
been switched to a new antidepressant (monotherapy) for 24 weeks or less.
Exclusion Criteria
2. The subject has not switched antidepressants in the past and/or is not currently receiving an 
antidepressant at the time of Screening.
Revised Text
Inclusion Criteria
3. The subject is currently being treated with an antidepressant (monotherapy).
Exclusion Criteria
2. The subject is not currently receiving an antidepressant at the time of Screening.
Rationale for Amendment
This modification was deemed necessary to enhance enrollment into the study.
Pages 11 and 22, Section 2.0 and 7.2
Existing Text
5. The subject has a history of only responding to either combination or augmentation therapy in 
the current episode and has had been treated for more than a year without any period of 
remission.
Revised Text
5. The subject has a history of only responding to either combination or augmentation therapy in 
the current episode.
Rationale for Amendment
This modification was deemed necessary to enhance enrollment into the study.
Page 27, Section 9.1.9
Existing Text
Investigators must account for all subjects who sign informed consent. If the subject is withdrawn 
at the Screening Visit, the investigator should complete the CRF.

Study No. MDD-5003
Page 60 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
Revised Text 
Investigators must account for all subjects who sign informed consent. If the subject is withdrawn 
at the Screening Visit after signing the informed consent, the investigator should complete the 
CRF.
Rationale for Amendment
To provide further clarification regarding the documentation required at the time of screening.
Page 28, Section 9.1.11.2
Existing Text 
Revised Text
Rationale for Amendment
Clarification and update to the section to ensure accurate representation of protocol procedures and 
corrected the timing of the mood questions.
Page 39, Section 12.2
Existing Text
The investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms), 
copies of all paper CRFs and query responses, and detailed records of drug disposition to enable 
evaluations or audits from regulatory authorities, the sponsor or its designees.
Revised Text
The investigator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study-specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms), 
CCI
CCI

Study No. MDD-5003
Page 61 of 61
Protocol Incorporating Amendment No. 01
10 March 2017
CONFIDENTIAL
and copies of all paper CRFs and query responses to enable evaluations or audits from regulatory 
authorities, the sponsor or its designees.
Rationale for Amendment
This is an unblinded noninterventional study.
Page 42, Section 13.1.4
Existing Text
These derived cognitive performance parameters from the n-back will be correlated with 
performance on CANTAB measures of working memory (SWM), attention and concentration 
(RVP), and executive function (CANTAB SWM Strategy and One Touch Stockings) and 
self-reported ratings of cognitive symptoms (Cognitive Dysfunction Questionnaire), using a 
Pearson correlation coefficient, or nonparametric equivalent, depending on the observed 
distribution of data.
Revised Text
These derived cognitive performance parameters from the n-back will be correlated with 
performance on CANTAB measures of working memory (SWM), attention and concentration 
(RVP), and executive function (CANTAB SWM Strategy and One Touch Stockings) and 
self-reported ratings of cognitive symptoms (
), using a Pearson correlation coefficient, or 
nonparametric equivalent, depending on the observed distribution of data.
Rationale for Amendment
Clarified the name of the scale.
CCI



䢢
䢢
䢢
䢢
䢢
䢢
䢢
䢢
(/(&7521,&6,*1$785(6
Signed by 
Meaning of Signature 
Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 



 
 
 



 
 
 



 
 
 



 
 
 



 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 




 
 
 





GF
䣃䣯䣧䣰䣦䣯䣧䣰䣶䢢䢲䢳䢢䣶䣱䢢䣃䢢䣕䣫䣰䣩䣮䣧䢢䣅䣧䣰䣶䣧䣴䢢䣒䣫䣮䣱䣶䢢䣕䣶䣷䣦䣻䢢䣶䣱䢢䢢䣇䣸䣣䣮䣷䣣䣶䣧䢢䣔䣧䣣䣮䢢䣖䣫䣯䣧䢢䣒䣣䣵䣵䣫䣸䣧䢢䣣䣰䣦䢢䣃䣥䣶䣫䣸䣧䢢䣊䣫䣩䣪䢯䣈䣴䣧䣳䣷䣧䣰䣥䣻
䣅䣱䣩䣰䣫䣶䣫䣸䣧䢢䣣䣰䣦䢢䣏䣱䣱䣦䢢䣃䣵䣵䣧䣵䣵䣯䣧䣰䣶䢢䣆䣣䣶䣣䢢䣫䣰䢢䣏䣣䣬䣱䣴䢢䣆䣧䣲䣴䣧䣵䣵䣫䣸䣧䢢䣆䣫䣵䣱䣴䣦䣧䣴䢢䣗䣵䣫䣰䣩䢢䣆䣫䣩䣫䣶䣣䣮䢢䣙䣧䣣䣴䣣䣤䣮䣧䢢䣖䣧䣥䣪䣰䣱䣮䣱䣩䣻
0HGLFDO$IIDLUV$SSURYDO
0DU87&
&OLQLFDO2SHUDWLRQV$SSURYDO
0DU87&
%LRVWDWLVWLFV$SSURYDO
0DU87&
&OLQLFDO6FLHQFH$SSURYDO
0DU87&
3KDUPDFRYLJLODQFH$SSURYDO
0DU87&
PPD